Dizal Pharmaceutical's Zegfrovy has taken the EGFR inhibitor class into new territory after hitting the mark in a phase 3 trial as a first-line treatment for non-small cell lung cancer (NSCLC) with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results